Patents by Inventor Markus Follmann

Markus Follmann has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Substituted S-alaninate derivatives
    Patent number: 11912692
    Abstract: The invention relates to substituted S-alaninate derivatives and to processes for their preparation, and also to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular vascular disorders, preferably thrombotic or thromboembolic disorders and/or thrombotic or thromboembolic complications.
    Type: Grant
    Filed: August 11, 2023
    Date of Patent: February 27, 2024
    Assignee: Bayer Aktiengesellschaft
    Inventors: Hartmut Beck, Stefanie Mesch, Alexandros Vakalopoulos, Nils Pfaff, Stefanie Zimmermann, Markus Follmann, Elisabeth Kersten, Guillaume Levilain, Kartrin Partikel, Andreas Peter Broehl, Stefan Heitmeier, Julia Dietze-Torres, Lutz Lehmann, Kersten Matthias Gericke, Frank Süßmeier, Lars Bärfacker, Alexander Hillisch, Adrian Tersteegen, Anja Buchmüller, Christoph Gerdes
  • SUBSTITUTED S-ALANINATE DERIVATIVES
    Publication number: 20230391761
    Abstract: The invention relates to substituted S-alaninate derivatives and to processes for their preparation, and also to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular vascular disorders, preferably thrombotic or thromboembolic disorders and/or thrombotic or thromboembolic complications.
    Type: Application
    Filed: August 11, 2023
    Publication date: December 7, 2023
    Inventors: Hartmut Beck, Stefanie Mesch, Alexandros Vakalopoulos, Nils Pfaff, Stefanie Zimmermann, Markus Follmann, Elisabeth Kersten, Guillaume Levilain, Kartrin Partikel, Andreas Peter Broehl, Stefan Heitmeier, Julia Dietze-Torres, Lutz Lehmann, Kersten Matthias Gericke, Frank Süßmeier, Lars Bärfacker, Alexander Hillisch, Adrian Tersteegen, Anja Buchmüller, Christoph Gerdes
  • SUBSTITUTED 5-FLUORO-1H-PYRAZOLOPYRIDINES AND THEIR USE
    Publication number: 20220409618
    Abstract: The present application relates to novel substituted 5-fluoro-1H-pyrazolopyridines, to processes for their preparation, to their use alone or in combinations for the treatment and/or prophylaxis of diseases, and to their use for producing medicaments for the treatment and/or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of cardiovascular disorders.
    Type: Application
    Filed: August 18, 2022
    Publication date: December 29, 2022
    Applicant: Adverio Pharma GmbH
    Inventors: Markus Follmann, Johannes-Peter Stasch, Gorden Redlich, Jens Ackerstaff, Nils Griebenow, Walter Kroh, Andreas Knorr, Eva-Maria Becker, Frank Wunder, Volkhart Min-Jian Li, Elke Hartmann, Joachim Mittendorf, Karl-Heinz Schlemmer, Rolf Jautelat, Donald Bierer
  • SUBSTITUTED DIHYDROPYRAZOLO PYRAZINE CARBOXAMIDE DERIVATIVES
    Publication number: 20220324865
    Abstract: The invention relates to substituted dihydropyrazolo pyrazine carboxamide derivatives and to processes for their preparation, and also to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular cardiovascular disorders, preferably thrombotic or thromboembolic disorders, and diabetes, and also urogenital and ophthalmic disorders.
    Type: Application
    Filed: May 10, 2019
    Publication date: October 13, 2022
    Inventors: Steffen MUELLER, Rudolf SCHOHE-LOOP, Nuria ORTEGA HERNANDEZ, Frank SUESSMEIER, Eloisa JIMENEZ NUNEZ, Thomas BRUMBY, Niels LINDNER, Christoph GERDES, Elisabeth POOK, Anja BUCHMUELLER, Fabienne Zdenka GAUGAZ, Dieter LANG, Stefanie ZIMMERMANN, Alexander Helmut Michael EHRMANN, Michael GERISCH, Lutz LEHMANN, Andreas TIMMERMANN, Martina SCHAEFER, Georg SCHMIDT, Karl-Heinz SCHLEMMER, Markus FOLLMANN, Elisabeth KERSTEN, Vivian WANG, Xiang GAO, Yafeng WANG
  • Substituted 5-fluoro-1H-pyrazolopyridines and their use
    Patent number: 11439642
    Abstract: The present application relates to novel substituted 5-fluoro-1H-pyrazolopyridines, to processes for their preparation, to their use alone or in combinations for the treatment and/or prophylaxis of diseases, and to their use for producing medicaments for the treatment and/or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of cardiovascular disorders.
    Type: Grant
    Filed: July 2, 2020
    Date of Patent: September 13, 2022
    Assignee: ADVERIO PHARMA GMBH
    Inventors: Markus Follmann, Johannes-Peter Stasch, Gorden Redlich, Jens Ackerstaff, Nils Griebenow, Walter Kroh, Andreas Knorr, Eva-Maria Becker, Frank Wunder, Volkhart Min-Jian Li, Elke Hartmann, Joachim Mittendorf, Karl-Heinz Schlemmer, Rolf Jautelat, Donald Bierer
  • STIMULATORS AND/OR ACTIVATORS OF SOLUBLE GUANYLATE CYCLASE (SGC) IN COMBINATION WITH AN INHIBITOR OF NEUTRAL ENDOPEPTIDASE (NEP INHIBITOR) AND/OR AN ANGIOTENSIN AII ANTAGONIST AND THE USE THEREOF
    Publication number: 20220023246
    Abstract: The present invention relates to stimulators and activators of soluble guanylate cyclase in combination with an inhibitor of neutral endopeptidase and/or angiotensin AII antagonists and the use thereof for the treatment and/or prophylaxis of cardiovascular disorders, for example heart failure with preserved ejection fraction or heart failure with reduced ejection fraction, renal disorders, for example chronic kidney failure, urological disorders, lung disorders, disorders of the central nervous system, for regulation of cerebral perfusion, for example in the event of vascular cerebral states of dementia, for the treatment and/or prophylaxis of fibrotic disorders and other disease symptoms (e.g. end organ damage affecting the brain, kidney or heart).
    Type: Application
    Filed: October 5, 2021
    Publication date: January 27, 2022
    Applicant: BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Tobias MARQUARDT, Markus FOLLMANN, Johannes-Peter STASCH
  • Stimulators and/or activators of soluble guanylate cyclase (sGC) in combination with an inhibitor of neutral endopeptidase (NEP inhibitor) and/or an angiotensin AII antagonist and the use thereof
    Patent number: 11166932
    Abstract: The present invention relates to stimulators and activators of soluble guanylate cyclase in combination with an inhibitor of neutral endopeptidase and/or angiotensin AII antagonists and the use thereof for the treatment and/or prophylaxis of cardiovascular disorders, for example heart failure with preserved ejection fraction or heart failure with reduced ejection fraction, renal disorders, for example chronic kidney failure, urological disorders, lung disorders, disorders of the central nervous system, for regulation of cerebral perfusion, for example in the event of vascular cerebral states of dementia, for the treatment and/or prophylaxis of fibrotic disorders and other disease symptoms (e.g. end organ damage affecting the brain, kidney or heart).
    Type: Grant
    Filed: July 15, 2016
    Date of Patent: November 9, 2021
    Assignee: Bayer Pharma Aktiengesellschaft
    Inventors: Tobias Marquardt, Markus Follmann, Johannes-Peter Stasch
  • SUBSTITUTED 5-FLUORO-1H-PYRAZOLOPYRIDINES AND THEIR USE
    Publication number: 20200397785
    Abstract: The present application relates to novel substituted 5-fluoro-1H-pyrazolopyridines, to processes for their preparation, to their use alone or in combinations for the treatment and/or prophylaxis of diseases, and to their use for producing medicaments for the treatment and/or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of cardiovascular disorders.
    Type: Application
    Filed: July 2, 2020
    Publication date: December 24, 2020
    Applicant: Adverio Pharma GmbH
    Inventors: Markus Follmann, Johannes-Peter Stasch, Gorden Redlich, Jens Ackerstaff, Nils Griebenow, Walter Kroh, Andreas Knorr, Eva-Maria Becker, Frank Wunder, Volkhart Min-Jian Li, Elke Hartmann, Joachim Mittendorf, Karl-Heinz Schlemmer, Rolf Jautelat, Donald Bierer
  • Substituted 5-fluoro-1H-pyrazolopyridines and their use
    Patent number: 10736896
    Abstract: The present application relates to novel substituted 5-fluoro-1H-pyrazolopyridines, to processes for their preparation, to their use alone or in combinations for the treatment and/or prophylaxis of diseases, and to their use for producing medicaments for the treatment and/or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of cardiovascular disorders.
    Type: Grant
    Filed: May 16, 2018
    Date of Patent: August 11, 2020
    Assignee: ADVERIO PHARMA GMBH
    Inventors: Markus Follmann, Johannes-Peter Stasch, Gorden Redlich, Jens Ackerstaff, Nils Griebenow, Walter Kroh, Andreas Knorr, Eva-Maria Becker, Frank Wunder, Volkhart Min-Jian Li, Elke Hartmann, Joachim Mittendorf, Karl-Heinz Schlemmer, Rolf Jautelat, Donald Bierer
  • STIMULATORS AND/OR ACTIVATORS OF SOLUBLE GUANYLATE CYCLASE (SGC) IN COMBINATION WITH AN INHIBITOR OF NEUTRAL ENDOPEPTIDASE (NEP INHIBITOR) AND/OR AN ANGIOTENSIN AII ANTAGONIST AND THE USE THEREOF
    Publication number: 20190125709
    Abstract: The present invention relates to stimulators and activators of soluble guanylate cyclase in combination with an inhibitor of neutral endopeptidase and/or angiotensin AII antagonists and the use thereof for the treatment and/or prophylaxis of cardiovascular disorders, for example heart failure with preserved ejection fraction or heart failure with reduced ejection fraction, renal disorders, for example chronic kidney failure, urological disorders, lung disorders, disorders of the central nervous system, for regulation of cerebral perfusion, for example in the event of vascular cerebral states of dementia, for the treatment and/or prophylaxis of fibrotic disorders and other disease symptoms (e.g. end organ damage affecting the brain, kidney or heart).
    Type: Application
    Filed: July 15, 2016
    Publication date: May 2, 2019
    Applicant: BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Tobias MARQUARDT, Markus FOLLMANN, Johannes-Peter STASCH
  • SGC stimulators in combination with additional treatment for the therapy of cystic fibrosis
    Patent number: 10265314
    Abstract: The present invention relates to soluble guanylate cyclase (sGC) and to phosphodiesterases (PDEs) and the pharmacology of sGC stimulators, sGC activators and PDE inhibitors (PDE5i) in combination with a) treatments, leading to increased cGMP mobilization, and/or b) tretaments correcting and/or potentiatiating CFTR function, and/or c) treatments currently used as standard of care in Cystic Fibrosis, and/or d) antinflammatory treatments for the preparation of medicaments for the treatment of Cystic Fibrosis (CF) with improved efficacy over methods of treatments already known.
    Type: Grant
    Filed: July 21, 2014
    Date of Patent: April 23, 2019
    Assignee: BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Peter Sandner, Johannes-Peter Stasch, Michael Hahn, Markus Follmann
  • Use of sGC stimulators, sGC activators, alone and combinations with PDE5 inhibitors for the treatment of systemic sclerosis (SSc)
    Patent number: 10189856
    Abstract: The use of sGC stimulators, sGC activators alone, or in combination with PDE5 inhibitors for the prevention and treatment of fibrotic diseases, such as systemic sclerosis, scleroderma, and the concomitant fibrosis of internal organs.
    Type: Grant
    Filed: May 24, 2011
    Date of Patent: January 29, 2019
    Assignee: Adverio Pharma GMBH
    Inventors: Claudia Hirth-Dietrich, Peter Sandner, Johannes-Peter Stasch, Andreas Knorr, Georges Von Degenfeld, Michael Hahn, Markus Follmann
  • SUBSTITUTED 5-FLUORO-1H-PYRAZOLOPYRIDINES AND THEIR USE
    Publication number: 20180263981
    Abstract: The present application relates to novel substituted 5-fluoro-1H-pyrazolopyridines, to processes for their preparation, to their use alone or in combinations for the treatment and/or prophylaxis of diseases, and to their use for producing medicaments for the treatment and/or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of cardiovascular disorders.
    Type: Application
    Filed: May 16, 2018
    Publication date: September 20, 2018
    Applicant: ADVERIO PHARMA GMBH
    Inventors: Markus FOLLMANN, Johannes-Peter STASCH, Gorden REDLICH, Jens ACKERSTAFF, Nils GRIEBENOW, Walter KROH, Andreas KNORR, Eva-Maria BECKER, Frank WUNDER, Volkhart Min-Jian LI, Elke HARTMANN, Joachim MITTENDORF, Karl-Heinz SCHLEMMER, Rolf JAUTELAT, Donald BIERER
  • Amino-substituted imidazo[1,2-a]pyridinecarboxamides and their use
    Patent number: 10052312
    Abstract: The present application relates to novel substituted imidazo[1,2-a]pyridine-3-carboxamides, to processes for their preparation, to their use alone or in combinations for the treatment and/or prophylaxis of diseases and to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of cardiovascular disorders.
    Type: Grant
    Filed: March 2, 2017
    Date of Patent: August 21, 2018
    Assignee: BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Alexandros Vakalopoulos, Markus Follmann, Ingo Hartung, Philipp Buchgraber, Rolf Jautelat, Jorma Haβfeld, Niels Lindner, Alexey Gromov, Frank Wunder, Johannes-Peter Stasch, Gorden Redlich, Volkhart Min-Jian Li, Eva Maria Becker-Pelster, Andreas Knorr
  • 5-aminotetrahydroquinoline-2-carboxylic acids and their use
    Patent number: 10053428
    Abstract: The present application relates to novel 5-amino-5,6,7,8-tetrahydroquinoline-2-carboxylic acids, to processes for their preparation, to their use for the treatment and/or prevention of diseases, and to their use for producing medicaments for the treatment and/or prevention of diseases, especially for the treatment and/or prevention of cardiovascular and cardiopulmonary disorders.
    Type: Grant
    Filed: May 19, 2017
    Date of Patent: August 21, 2018
    Assignee: BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Michael Hahn, Markus Follmann, Eva-Maria Becker, Johannes-Peter Stasch, Joerg Keldenich, Martina Delbeck, Hanna Tinel, Frank Wunder, Joachim Mittendorf, Ildiko Terebesi, Dieter Lang, René Martin, Walter Hübsch
  • THE USE OF SGC STIMULATORS, SGC ACTIVATORS, ALONE AND COMBINATIONS WITH PDE5 INHIBITORS FOR THE TREATMENT OF DIGITAL ULCERS (DU) CONCOMITANT TO SYSTEMIC SCLEROSIS (SSC)
    Publication number: 20180169095
    Abstract: Use of sGC stimulators, sGC activators alone, or in combination with PDE5 inhibitors for the prevention and healing of Digital Ulcers which are concomitant to fibrotic diseases, such as systemic sclerosis and scleroderma.
    Type: Application
    Filed: May 2, 2016
    Publication date: June 21, 2018
    Applicant: Bayer Pharma Aktiengesellschaft
    Inventors: Claudia HIRTH-DIETRICH, Peter SANDNER, Johannes-Peter STASCH, Michael HAHN, Markus FOLLMANN, Alexandros VAKALOPOULOS
  • Substituted 5-flouro-1H-pyrazolopyridines and their use
    Patent number: 9993476
    Abstract: The present application relates to novel substituted 5-fluoro-1H-pyrazolopyridines, to processes for their preparation, to their use alone or in combinations for the treatment and/or prophylaxis of diseases, and to their use for producing medicaments for the treatment and/or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of cardiovascular disorders.
    Type: Grant
    Filed: November 10, 2016
    Date of Patent: June 12, 2018
    Assignee: ADVERIO PHARMA GMBH
    Inventors: Markus Follmann, Johannes-Peter Stasch, Gorden Redlich, Jens Ackerstaff, Nils Griebenow, Walter Kroh, Andreas Knorr, Eva-Maria Becker, Frank Wunder, Volkhart Min-Jian Li, Elke Hartmann, Joachim Mittendorf, Karl-Heinz Schlemmer, Rolf Jautelat, Donald Bierer
  • 3-aryl-substituted imidazo[1,2-A]pyridines and their use
    Patent number: 9776997
    Abstract: The present application relates to novel 3-aryl-substituted imidazo[1,2-a]pyridines, to processes for preparation thereof, to the use thereof, alone or in combinations, for treatment and/or prophylaxis of diseases, and to the use thereof for production of medicaments for treatment and/or prophylaxis of diseases, especially for treatment and/or prophylaxis of cardiovascular disorders.
    Type: Grant
    Filed: June 4, 2014
    Date of Patent: October 3, 2017
    Assignee: BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Alexandros Vakalopoulos, Markus Follmann, Ingo Hartung, Philipp Buchgraber, Alexey Gromov, Niels Lindner, Frank Wunder, Johannes-Peter Stasch, Gorden Redlich, Volkhart Min-Jian Li
  • SUBSTITUTED 5-FLUORO-1H-PYRAZOLOPYRIDINES AND THEIR USE
    Publication number: 20170273977
    Abstract: The present application relates to novel substituted 5-fluoro-1H-pyrazolopyridines, to processes for their preparation, to their use alone or in combinations for the treatment and/or prophylaxis of diseases, and to their use for producing medicaments for the treatment and/or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of cardiovascular disorders.
    Type: Application
    Filed: November 10, 2016
    Publication date: September 28, 2017
    Applicant: ADVERIO PHARMA GMBH
    Inventors: Markus FOLLMANN, Johannes-Peter STASCH, Gorden REDLICH, Jens ACKERSTAFF, Nils GRIEBENOW, Walter KROH, Andreas KNORR, Eva-Maria BECKER, Frank WUNDER, Volkhart Min-Jian LI, Elke HARTMANN, Joachim MITTENDORF, Karl-Heinz SCHLEMMER, Rolf JAUTELAT, Donald BIERER
  • Cyano-substituted imidazo[1,2-A]pyridinecarboxamides and their use
    Patent number: 9771360
    Abstract: The present application relates to novel substituted imidazo[1,2-a]pyridine-3-carboxamides, to processes for preparation thereof, to the use thereof, alone or in combinations, for the treatment and/or prophylaxis of diseases, and to the use thereof for production of medicaments for the treatment and/or prophylaxis of diseases, especially for the treatment and/or prophylaxis of cardiovascular disorders.
    Type: Grant
    Filed: March 18, 2015
    Date of Patent: September 26, 2017
    Assignee: BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Alexandros Vakalopoulos, Philipp Buchgraber, Niels Lindner, Markus Follmann, Frank Wunder, Johannes-Peter Stasch, Tobias Marquardt, Gorden Redlich, Lisa Dietz, Volkhart Min-Jian Li